XKRX
004720
Market cap46mUSD
Oct 08, Last price
2,860.00KRW
1D
-2.05%
1Q
-6.23%
Jan 2017
-83.42%
Name
PharmGen Science Inc
Chart & performance
P/E
—
P/S
0.36
EPS
—
Div yield, %
—
Shrs. gr., 5y
7.89%
Rev. gr., 5y
12.37%
Revenues
173.07b
+1.04%
Net income
-116.64b
L
CFO
5.32b
+123.20%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PharmGen Science, Inc., originally founded in 1961 as Wooridul Pharmaceutical Limited, is a South Korean company primarily involved in the research, development, manufacturing, and distribution of pharmaceutical products. Based in Hwaseong, South Korea, the firm offers a diverse portfolio encompassing prescription medications, over-the-counter drugs, nutritional supplements, and cosmetic items. These are available in various forms, including tablets, hard capsules, granules, ointments, syrups, and suspensions.
Key people
Ui Sang Han
Chairman · since 2022
Hye Yeon Kim
Co-Chief Executive Officer, Director · since 2019
Geun Hyeong Lee
Vice Chairman · since 2022
Nam Hyeon Ryu
Vice Chairman · since 2020
Jae Man Yoo
Internal Auditor · since 2025
Yeong Ho Choi
Director · since 2022
Hui Deok Park
Co-Chief Executive Officer, Director · since 2019
Non-Executive Independent Director · since 2023
Chung Wu Kim
Non-Executive Independent Director · since 2023
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||